Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698815 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
A Phase 2 study of Recurrent Non-Small Cell Lung Carcinoma and Stage IV Non-Small Cell Lung Cancer AJCC v7, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT00698815 is a Phase 2 study of Recurrent Non-Small Cell Lung Carcinoma and Stage IV Non-Small Cell Lung Cancer AJCC v7 that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 130 participants, above the 105-participant average among 6 other Recurrent Non-Small Cell Lung Carcinoma trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 1 state.
The verdict
NCT00698815, a Phase 2 study of Recurrent Non-Small Cell Lung Carcinoma and Stage IV Non-Small Cell Lung Cancer AJCC v7, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether pemetrexed disodium and sunitinib malate are more effective when given alone or together in treating non-small cell lung cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Pemetrexed Disodium
- DRUG Sunitinib Malate
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Arroyo Grande Community - Arroyo Grande
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- East Bay Radiation Oncology Center - Castro Valley
- Eden Hospital Medical Center - Castro Valley
- Valley Medical Oncology Consultants-Castro Valley - Castro Valley
- Bay Area Breast Surgeons Inc - Emeryville
- Kaiser Permanente Hospital - Fontana
- Valley Medical Oncology Consultants-Fremont - Fremont
- Kaiser Permanente - Harbor City - Harbor City
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Kaiser Permanente-Cadillac - Los Angeles
- Contra Costa Regional Medical Center - Martinez
- El Camino Hospital - Mountain View
- Highland General Hospital - Oakland
- Alta Bates Summit Medical Center - Summit Campus - Oakland
- Bay Area Tumor Institute - Oakland
- Hematology and Oncology Associates-Oakland - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698815
The ClinicalTrials.gov registry entry for NCT00698815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 105-participant average among 6 other Recurrent Non-Small Cell Lung Carcinoma trials with a reported enrollment target (24% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Non-Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00698815 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00698815 about?
NCT00698815 is a clinical study titled "Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer". This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as pemetrexed disodium, work...
What is the current status of trial NCT00698815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2008-04-15.
What conditions does trial NCT00698815 study?
This clinical trial studies the following conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7.
What interventions are being tested in trial NCT00698815?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pemetrexed Disodium (DRUG), Sunitinib Malate (DRUG).
Who is sponsoring clinical trial NCT00698815?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00698815 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Non-Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
COMPLETED · Phase 2
-
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
COMPLETED · Phase 2
-
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Non-Small Cell Lung Carcinoma
All registered trials for this condition
Stage IV Non-Small Cell Lung Cancer AJCC v7
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.